Citigroup’s Inozyme Pharma INZY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $5.56K | Sell |
1,390
-36,748
| -96% | -$147K | ﹤0.01% | 4524 |
|
|
2025
Q1 | $34.7K | Sell |
38,138
-2,265
| -6% | -$2.06K | ﹤0.01% | 4211 |
|
|
2024
Q4 | $112K | Buy |
40,403
+2,754
| +7% | +$7.63K | ﹤0.01% | 3935 |
|
|
2024
Q3 | $197K | Buy |
37,649
+25,969
| +222% | +$136K | ﹤0.01% | 3589 |
|
|
2024
Q2 | $52.1K | Buy |
11,680
+2,652
| +29% | +$11.8K | ﹤0.01% | 3826 |
|
|
2024
Q1 | $69.2K | Buy |
9,028
+2,287
| +34% | +$17.5K | ﹤0.01% | 3727 |
|
|
2023
Q4 | $28.7K | Buy |
6,741
+6,723
| +37,350% | +$28.6K | ﹤0.01% | 4082 |
|
|
2023
Q3 | $75 | Sell |
18
-10,062
| -100% | -$41.9K | ﹤0.01% | 4702 |
|
|
2023
Q2 | $56.1K | Buy |
+10,080
| New | +$56.1K | ﹤0.01% | 3906 |
|
|
2022
Q3 | – | Sell |
-143
| Closed | -$1K | – | 5182 |
|
|
2022
Q2 | $1K | Sell |
143
-12,374
| -99% | -$86.5K | ﹤0.01% | 5230 |
|
|
2022
Q1 | $51K | Buy |
12,517
+8,853
| +242% | +$36.1K | ﹤0.01% | 4020 |
|
|
2021
Q4 | $25K | Buy |
3,664
+560
| +18% | +$3.82K | ﹤0.01% | 4563 |
|
|
2021
Q3 | $36K | Buy |
3,104
+996
| +47% | +$11.6K | ﹤0.01% | 4174 |
|
|
2021
Q2 | $36K | Buy |
2,108
+863
| +69% | +$14.7K | ﹤0.01% | 4297 |
|
|
2021
Q1 | $25K | Sell |
1,245
-991
| -44% | -$19.9K | ﹤0.01% | 4444 |
|
|
2020
Q4 | $46K | Buy |
2,236
+1,846
| +473% | +$38K | ﹤0.01% | 4146 |
|
|
2020
Q3 | $10K | Buy |
+390
| New | +$10K | ﹤0.01% | 4311 |
|